Amgen (AMGN) Tops Q1 EPS by 7c; offers guidance
Get Alerts AMGN Hot Sheet
Price: $437.23 -1.55%
Revenue Growth %: +5.1%
Financial Fact:
Total operating expenses: 3.28B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +5.1%
Financial Fact:
Total operating expenses: 3.28B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Amgen (NASDAQ: AMGN) reported Q1 EPS of $3.96, $0.07 better than the analyst estimate of $3.89. Revenue for the quarter came in at $7.45 billion versus the consensus estimate of $7.45 billion.
GUIDANCE:
Amgen sees FY2024 EPS of $19.00-$20.20, versus the consensus of $19.53. Amgen sees FY2024 revenue of $32.5-33.8 billion, versus the consensus of $32.956 billion.
For earnings history and earnings-related data on Amgen (AMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Amgen (AMGN) PT Raised to $435 at Wells Fargo
- Campbell Soup (CPB) Reports In-Line Q4 EPS, Misses on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share